论文部分内容阅读
舒普深(Sulperazon)为头孢哌酮和舒巴坦复合制剂,我院自1998年以来应用该药治疗内科感染性疾患,取得很好的疗效,现将临床观察报告如下。1 对象与方法1.1 病例资料 选择有感染临床征象并细菌学证实,采用常规抗生素治疗无效的病人。共应用舒普深抗感染治疗20例,其中男12例,女8例;年龄16～80岁,平均55岁。包括肺炎2例,肺脓肿1例,余者为原有慢性肺部疾患或肿瘤性疾患基础上的继发感染。基础疾患中慢性阻塞性肺疾患4例,支气管扩张1例,肺癌6例,骨转移癌1例,胃癌2例,肝癌3例。所有病例均为呼吸系统感染,伴有发热、咳嗽、咳白色或黄白色粘膜,肺部可闻及湿罗音。12例肿瘤病人中
Sulperazon (Sulperazon) cefoperazone and sulbactam combination preparation, our hospital since 1998, the drug treatment of medical infectious diseases, and achieved good results, the clinical observations are as follows. 1 Subjects and methods 1.1 The choice of case data have clinical signs of infection and confirmed bacteriology, the use of conventional antibiotics in patients with ineffective treatment. A total of 20 cases of Shu Pu deep anti-infection treatment, including 12 males and 8 females; aged 16 to 80 years, mean 55 years. Including pneumonia in 2 cases, 1 case of lung abscess, the remaining for the original chronic lung disease or neoplastic disease based on secondary infection. 4 cases of chronic obstructive pulmonary disease in underlying diseases, bronchiectasis in 1 case, 6 cases of lung cancer, 1 case of bone metastasis, 2 cases of gastric cancer, 3 cases of liver cancer. All cases were respiratory infections with fever, cough, white or yellowish white mucous membranes, lungs and wet rales. 12 cases of cancer patients